[Clinical values of serum PGGT (pancreas gamma-glutamyltranstidase and PGGT/TGGT ratio in diagnosis of cancer of the head of pancreas].

737 samples of sera were determined for gamma-glutamyl transtidase Iscenzyme (PGGT). The samples were obtained from 121 healthy adults, forty pancreatic-head-cancer patients, and 576 patients with other hepato-biliary-pancreatic diseases. The positive rates of PGGT greater than 4u/l and PGGT/TGGT greater than 0.1 were 62.5% (25/40) in pancreatic-head-cancer patients, 27.02% (10/37) in patients with non-pancreatic extrahapatic-biliary-duct malignant obstructive jaundice, 1.21% (1/82) in patients with benign extrahepatic-biliary duct obstructive jaundice (biliary stones), 1.29% (1/77) in liver cancer patients, and 0% (0/380) in patients with other general surgical diseases, respectively. The positive rate of PGGT greater than 4u/L and PGGT/TGGT greater than 0.1 was significantly higher in patients with pancreatic head cancer than in patients with hepato-biliary-duct obstructive jaundice (including benign and malignant diseases) and liver cancer (x = 99.45, p less than 0.001). The study showed that the serum TGGT was mainly of hepatic origin, and its level was elevated in patients with pancreatic or/and biliary diseases, which resulted in the obstruction of the pancreatic duct and bile duct at the same time. Hence, the serum PGGT greater than 4u/L together with POGT/TGGT greater than 0.1 was mainly found in patients with pancreatic head cancer.